AnaptysBio
Update in progressANAB (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
AnaptysBio, Inc. is a clinical‑stage biotech company developing immunology therapies for autoimmune and inflammatory diseases in the United States. Its pipeline includes Rosnilimab (a T cell–depleting antibody) for rheumatoid arthritis in Phase 2b; ANB033 (CD122 antagonist) in Phase 1b for celiac disease and eosinophilic esophagitis; ANB101 (BDCA2 antibody) in Phase 1a; dostarlimab (PD‑1) for solid tumors; and Imsidolimab (IL‑36R inhibitor) in Phase 3 for generalized pustular psoriasis. It collaborates with GSK and Vanda. Formerly Anaptys Biosciences, renamed in 2006. Founded 2005, based in San Diego, CA.
Company score
- Sentiment
- 0.11
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- -0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Daniel R. Faga
- Founded2005
- Employees104
- Websitewww.anaptysbio.com
Identifiers
- ISINUS0327241065
- FIGIBBG0026ZDHR0
- LEI529900HH4WQT03IG1A12
- CUSIP032724106
- CIK0001370053